Granata Bio

Granata Bio is a private, clinical-stage biopharma company targeting the underserved US fertility therapeutics market. The company employs a capital-efficient 'search and develop' model, in-licensing established IVF medications from outside the US and advancing them through clinical development and regulatory approval for the North American market. With a pivotal Phase III trial underway for a key gonadotropin asset and the 2025 acquisition of Oviva Therapeutics, Granata Bio is positioning itself as a new competitor aimed at increasing treatment options, spurring innovation, and potentially lowering costs for patients. The company is led by a team with deep reproductive health expertise and is supported by a network of stakeholders in the fertility field.

Strategic in-licensing and development engine for established reproductive health therapeutics, focusing on clinical development, regulatory strategy, and commercialization for the North American market.

Granata Bio competes in the fertility therapeutics market against large, established pharmaceutical companies (e.g., Merck KGaA, Ferring) that dominate the gonadotropin sector. Its strategy is to disrupt this landscape by introducing new competitors via in-licensing, aiming to compete on value and integration into clinical practice rather than novel discovery.